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Abstract
Background: Sulphadoxine and pyrimethamine are anti-folate drugs that show synergistic anti-malarial effect.
Point mutations in dihydrofolate reductase (dhfr) and dihydropteorate synthatase (dhps) cause anti-folate drug
resistance phenotype in human malaria parasites. This study presents pattern of point mutations in dhfr/dhps genes
among Indian sub-continent.
Methods: Microscopically diagnosed one hundred Plasmodium vivax field isolates were collected from five widely
separated geographical regions of India. Dhfr and dhps genes were PCR amplified and sequenced. Previously
published mutations data were collected and analyzed using Chi square test to identify geographical cluster of
mutant/wild type genotypes.
Results: Sequence analysis revealed single (S58R), double (S58R/S117N) and quadruple (F57L/S58R/T61M/S117T/)
point mutations at dhfr and single (A383G) to double (A383G/A553G) mutations at dhps in P. vivax field isolates.
In addition, three new mutations were also observed at dhfr. Both, dhfr and dhps genes revealed tandem repeat
variations in field isolates. Dhps revealed very low mutation frequency (14.0%) compared to dhfr (50.70%).
Comparative analysis revealed a progressive increase in frequency of quadruple mutant dhfr genotype (p < 0.001)
within five years in north-eastern state (Kamrup, Assam). Frequency of dhfr genotypes revealed three distinct
geographical clusters of wild (northern India), double mutant (southern India), and quadruple mutant (north-
eastern and island regions of India) on the Indian sub-continent.
Conclusion: Study suggests that SP may be susceptible to P. vivax in India, except Andaman and north-eastern
state. The distinction of geographical regions with sensitive and resistant parasite phenotypes would be highly
useful for designing and administering national anti-malarial drug policy.
Background
Malaria is a life-threatening ancient parasitic disease and
causes 250-500 million clinical episodes and nearly one
million deaths annually [1]. Among the five human
malaria species, Plasmodium falciparum is the most
severe form, causing malignant malaria globally, while
Plasmodium vivax is the most widespread species out-
side Africa, causing huge morbidity and can be severe
and fatal [2-7].
The worldwide spread of chloroquine (CQ) resistant
strains of P. falciparum has led to use of sulphadoxine-
pyrimethamine (SP) as the first-line anti-malarial drug
in Southeast Asian countries. Sulphadoxine and
pyrimethamine sequentially inhibits dihydropteroate
synthase (DHPS) and dihydrofolate reductase (DHFR)
enzymes respectively in the folate biosynthesis pathway
resulting synergistic anti-malarial effect [8]. Parasite has
overcome the effect of SP by evolving point mutations
in the respective genes encoding enzymes involved in
the folate biosynthesis pathway. The mutated DHPS and
DHFR enzymes have reduced binding affinity with SP
drug and thus parasite survives in the presence of drug
[9,10].
In India, resistance to CQ was reported for the first
time in 1973 in P. falciparum from north-eastern states
[11] and later it spread throughout the country [12]. To
overcome CQ resistance problem, in 1982, SP was
employed as first-line anti-malarial therapy for treat-
ment of falciparum malaria in areas with >25% CQ
resistant level, complicated malaria case, and higher
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national anti-malarial drug policy, artimisinin-based
combination therapy (ACT) (Artesunate+SP) is being
used in most of the malaria endemic regions [12].
Reduced susceptibility to CQ in P. vivax was for the
first time observed in 1989 in Australian soldiers
returned from Papua New Guinea [13]. Later, several
cases from Papua New Guinea, Indonesia, New Guinea,
Brazil and India were documented [14-19]. Recent stu-
dies from P. vivax ex-vivo maturation experiment
showed reduction in the susceptibility to CQ in South-
east Asian counties [20,21]. This information indicates
gradual increase in CQ resistance cases of P. vivax.
India contributes more than 78% of total malaria cases
of Southeast Asia and P. vivax accounts for more than
50% of annual malaria cases [22]. Point mutations in
P. vivax dhfr had been documented from different parts
of India [23-25], however mutation data of dhps is yet
to identified in order to understand the molecular
epidemiology of anti-folate resistance. Therefore, identi-
fying information about presence of anti-folate drug
resistance related point mutations (dhfr/dhps)i n
P. vivax from Indian sub continent would be highly
helpful to understand the global pattern of anti-folate
drug resistance. This study aims to identify point muta-
tions in dhfr/dhps and the spatio temporal pattern of
anti-folate drug resistance in Indian sub-continent.
Methods
Study sites and sample collection
Blood samples were collected from five widely separated
geographical regions of the Indian subcontinent namely
Delhi (2005); Chennai, Tamil Nadu (2005); Kamrup,
Assam (2007); Nadiad, Gujarat (2005) and Panna, Mad-
hya Pradesh (2006). Details of epidemiological and geo-
graphical information about study sites are reported
elsewhere [26]. Finger prick blood was spotted on auto-
claved Whatman filter paper strips (Number 3) from the
symptomatic patients in active case detection surveys as
well as from patient attending clinics. A total of 100
microscopically-diagnosed P. vivax positive blood sam-
ples were spotted and dried blood spots were stored at
4.0°C. Only P. vivax infected samples were included in
this study. This study was approved by the ethics com-
mittee of the National Institute of Malaria Research,
New Delhi. All blood spots were collected only after
obtaining consent of the patients.
DNA extraction, PCR, and DNA sequencing
Genomic DNA was extracted from blood spots using
QIAamp mini DNA kit (Qiagen, Germany) according to
manufacturer instructions. Genomic DNA was eluted in
120.0 μl triple sterile water and store in -20°C until use.
One step modified PCR strategy was employed for
amplification of dhfr/dhps using nested primers reported
earlier [27,28]. The modified PCR conditions for dhfr was-
initial denaturation at 95°C/5.0 minute, denaturation at
95°C/30 second, annealing at 64°C/30 second, and exten-
sion at 72°C/60 second for 40 cycle, and a final extension
at 72°C/5.0 minute. The modified PCR amplification for
dhps was same as dhfr except annealing step, which is
55°C/30 second. PCR products were purified with Exonu-
clease I/Shrip alkaline phosphates treatment according to
manufacturer instruction (Fermentas, USA). Purified PCR
products were outsourced to Macrogen Inc, Korea for
DNA sequencing [29]. Each sample was sequenced with
both forward and reverse primers. DNA sequences were
edited and aligned (ClustalW method) with EditSeq and
MegAlign module of DNA Lasergene software version 7.0
(Madison, USA). Samples that show novel point mutations
were re-sequenced from another independent PCR pro-
duct. All sequences have been submitted to the GenBank
(EU149665-EU149764, EU145878-EU145947).
Collection of dhfr mutations data and statistical analysis
Dhfr point mutations data from Panna, Madhya Pradesh
(N = 30); Nadiad, Gujarat (N = 19); Mukherji Nagar,
Delhi (N = 68); Cuttack, Orissa (N = 16); Mohan Nagar
(N = 49) Aligarh (N = 38) and Mirzapur (N = 8), Uttar
Pradesh; Chennai, Tamil Nadu (N = 67) Car Nicobar,
Andaman Nicobar (N = 38); Panjim, Goa (N = 76);
Kamrup, Assam (N = 24) and Navi Mumbai, Maharash-
tra (N = 24) were collected from the earlier studies
[23-25,30]. On the basis of mutations in dhfr and
geographical location, grouping between different geo-
graphical regions was done. Geographical regions were
grouped according to the higher prevalence of wild type,
double mutant, and quadruple mutant dhfr genotypes.
Chi square test was done to check the significance of
prevalence of dhfr mutant genotypes in geographical
locations. Confidence interval at 95% was done to check
the proportion dhfr genotypes in each group.
Results
Mutations analysis in dhfr and dhps
For dhfr,at o t a lo f7 1P. vivax isolates were successfully
PCR amplified and sequenced. PCR amplified dhfr was
711 bp in length and covers complete coding region. All
sequences were compared with wild type reference
sequence (GenBank accession no. X98123) to detect
point mutations in dhfr. Point mutations observed at
dhfr were given in table 1. Approximately 50% (35/71)
sequences at dhfr were wild type. DNA sequence align-
ment revealed point mutations at 57(F®L), 58(S®R), 61
(T®M), 64(V®L), 117(S®T), and 173(I®F). Point
mutations at codon 64 (V®L) and 173 (I®F) were first
time observed in the Indian isolates. One isolate showed
amino acid substitution (57F®L) by changing nucleotide
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analysis revealed two synonymous mutations at codon
69Y (TAT®TAC) and 134 V (GTC®GTT). Synon-
ymous mutation 134 V (GTC®GTT) is novel and
observed only in the wild type dhfr genotype. The
majority of the mutated codons were S58R (47.88%),
S117N/T (46.47%), F57L (21.12%), and T61M (19.71%).
Study isolates revealed single (S58R), double (S58R/
S117N) and quadruple (F57L/S58R/T61M/S117T/)
mutations.
For dhps, a total of 100 P. vivax isolates were success-
fully PCR amplified (950 bp) which covers hotspot
region for drug resistance related point mutations
(codon 350 to 652). All sequences were compared with
wild type reference sequence (GenBank accession no.
AY186730) to detect point mutations in dhps. Sequence
analysis revealed point mutation at codon A383G and
A583G (Table 1). Majority of the sequences were wild
type (86%). Only single (A383G) and double (A383G/
A583G) point mutations were observed at dhps in the
study isolates (Table 1).
Geographical distribution of dhfr and dhps genotypes
Four distinct genotypes of dhfr were observed and
these are wild type, single mutant, double mutant and
quadruple mutant. In total, among mutant genotypes,
frequency of double mutant (28.16%) and quadruple
mutant (19.71%) was higher compared with single
mutant (2.81%). Isolates of Panna, Delhi, and Nadiad
were dominated by wild type genotype (Table 2).
Frequency of mutant dhfr genotypes was highest in
isolates of Chennai (84.24%) and Kamrup (66.67%)
regions. In contrast, isolates from Delhi (9.0%), Panna
(23.52%), and Nadiad (33.34%) showed relatively low
proportion of mutant genotypes. Geographical distribu-
tion of various genotypes observed at dhfr is given in
Table 2. Double mutant genotype was observed to be
predominated in Chennai isolates (78.94%) whereas
quadruple mutant genotype was dominated in Kamrup
region (61.90%). The silent point mutation T69C was
observed in wild type dhfr sequences only. The point
mutation T69C was found at a high frequency in iso-
lates of Panna (47.05%) but in lesser extent in Delhi
(18.18%) and Chennai (5.26%) isolates. Another silent
point mutation C134T was limited to isolates of Panna
(11.76%).
Three distinct dhps genotypes were observed in the
field isolates: wild type, single mutant and double
mutant. The wild type genotype was observed in high
frequency in field isolates of Delhi (85%) and Chennai
(55%) whereas isolates from Panna, Nadiad, and Kamrup
were exclusively wild type. The mutant genotypes (single
and double) were only observed in isolates from Delhi
and Chennai (Table 2).
Tandem repeat variation, distribution, and association
with mutations
At dhfr, four tandem repeat variants were observed and
designated as Type 1-4, on the basis of six amino acid
deletion/insertion (Figure 1). In total, tandem repeat
Type 2 (84.50%) was the major repeat polymorph
observed in field isolates (Table 3). Type 2 tandem
repeat was observed in high frequency in all study sites
except for Delhi where Type 1 predominates. Distribu-
tion of tandem repeat variants in different study sites is
given in Table 3. Tandem repeat variant was mono-
morphic (Type-2) in field isolates of Nadiad, Chennai
and Kamrup, whereas it was polymorphic in field iso-
lates of Delhi and Panna. This suggests that
Table 1 Distribution of Plasmodium vivax dhfr/dhps point mutations in field isolates
DHFR DHPS
Regions Sample size Wild type F57L S58R T61M V64L S117N/T I173F T69C C134T Sample size Wild type A383G A553G
Nadiad 3 2 1 1 20 20
Delhi 11 10 1 2 20 17 3 3
Panna 17 13 4 3 82 20 20
Chennai 19 3 1 16 1 16 1 20 9 11 8
Kamrup 21 7 14 13 13 13 1 20 20
Total 71 35 15 34 14 1 33 1 11 2 100 86 14 11
Boldface: synonymous substitution.
Values indicate number of isolates.
Table 2 Region wise distribution of Plasmodium vivax
dhfr and dhps genotypes
DHFR (%) DHPS (%)
Region Sample
size
WT SM DM QM Sample
size
WT SM DM
Nadiad 3 66.67 33.33 20 100
Delhi 11 90.9 9.1 20 85 15
Panna 17 76.47 5.88 17.65 20 100
Chennai 19 15.79 78.95 5.26 20 45 15 40
Kamrup 21 33.34 4.76 61.9 20 100
Total 71 49.29 2.81 28.16 19.71 100 86 3 11
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observed in a region where mutant dhfr genotypes pre-
dominate. In study isolates, all mutant dhfr genotypes
were observed in isolates having Tandem repeat Type-2.
At dhps, eight tandem repeats variants were observed
and designated as Type A-H on the basis of deletion/
insertion of seven amino acid repeat whereas (Figure 2).
Tandem repeat Type-B was the major variant in the
field isolates (75.25%) and predominate in all study sites
(Table 3). Distribution of tandem repeat variants in dif-
ferent study sites is given in Table 3. Seven tandem
repeat variants were found in field isolates of Kamrup,
three in Panna, Chennai, and Nadiad and only two in
Delhi. Point mutations were only observed in field iso-
lates having tandem repeat Type B.
Progressive increase in frequency of dhfr quadruple
mutant
In Kamrup region, dhfr point mutation data from 2002-
2003 revealed higher frequency of double mutant
(54.16%) and low prevalence of wild (29.16%) and quad-
ruple mutant (16.67%) genotypes [23]. Present study
conducted in 2006-2007 revealed quite surprising result
with respect to the data of dhfr point mutations studied
in 2002-03. In the present study a high prevalence of
the quadruple mutant genotype (61.90%) and an almost
absence of the double mutant genotype (4.16%) were
observed. However, the lower prevalence of wild type
remains the same. The interesting finding was the dras-
t i ci n c r e a s ei nt h ef r e q u e n c yo fq u a d r u p l em u t a n tdhfr
genotype in Kamrup region (p = <0.0001) within a five
year (2002 to 2007) span. This suggests that there is
progressive increase in the frequency of quadruple
mutant dhfr genotype.
Geographical clustering of dhfr genotypes among Indian
continent
Dhfr point mutations data of earlier published work (n =
477) revealed single to quadruple mutant genotypes with
their varied prevalence in different geographical regions
of India (Figure 3). Comprehensive analysis of dhfr
point mutations revealed three distinct pattern which
are- 1) high prevalence of wild type, 2) high prevalence
of double mutant type, and 3) high prevalence of quad-
ruple mutant type. On the basis of above categorization,
study sites were grouped together to see any trend of
significance between geographical location and preva-
lence of dhfr genotypes. Three distinct geographical
clusters were appeared at significant level (p < 0.0001).
These geographical clusters are- Type-1) covers geogra-
phical areas of North India and majority of isolates were
wild type (81.64%, 95% CI = ± 4.9) and very low propor-
tion of single and or double mutant. Type-2) covers
geographical areas of South India and majority of iso-
lates were double mutant type (80.54%, 95% CI = ±
6.22) and very low proportion of wild and single mutant
types. Type-3) covers geographical areas of north-east-
ern state and Island region where quadruple mutant
(42.68%, 95% CI = ± 10.72) predominate over wild
(29.26%) and double mutant type (28.04%). Details of
geographical regions falling in specific cluster are given
in figure 3. Comparison of Type-1 cluster with Type-2
or mutant versus wild types (p < 0.0001), and Type-2
cluster with Type-3 or double mutant versus quadruple
mutant (p < 0.0001) strongly supports grouping or clus-
tering of wild, double mutant, and quadruple mutant
dhfr genotypes in three distinct geographical regions of
the country.
256 QGGGDNTSGGDNTHGGDNTHGGDNADKLQT Type 1
256 QGGGDNTSGGDNTHG------GDNADKLQT Type 2
256 QGGGDNT------------HGGDNADKLQT Type 3
256 QGGGDNT------------SGGDNADKLQT Type 4
Figure 1 Tandem repeat variation in Plasmodium vivax DHFR.
Table 3 Distribution of tandem repeat variants at DHFR
and DHPS in field isolates
DHFR Regions (%) Total N
(%)
Repeat
Type
Delhi Nadiad Panna Chennai Kamrup
Type 1 54.54 0 11.76 0 0 8 (11.26)
Type 2 36.34 100 76.47 100 100 60 (84.5)
Type 3 9.09 0 0 0 0 1 (1.4)
Type 4 0 0 11.76 0 0 2 (2.81)
Total (N) 11 3 17 19 21 71
DHPS
Type A 10 10 0 5 21.05 9.27
Type B 90 85 83.34 90 26.31 75.25
Type C 0 0 5.55 5 0
Type D 0 5 5.55 0 15.79 5.15
Type E 0 0 0 0 10.52 2.06
Type F 0 0 0 0 10.52 2.06
Type G 0 0 5.55 0 10.52 3.09
Type H 0 0 0 0 5.26 1.03
Total (N) 20 20 18* 20 19* 97
*: DNA sequences of tandem repeat region was not good in some isolates
and therefore not included in analysis of tandem repeats.
 754 GEAKLTNGEGKLTNGEAKLTNGEGKLTNGEAKLTNGEGKLTNGDAKLTNGDSKLTNG Type A 
 754 GEAKLTNGEGKLTNGEAKLTNGEGKLTNG---------------------DSKLTNG Type B 
 754 GEAKLTNGEGKLTNGEAKLTNGEGKLTN--------------GDAKLTNGDSKLTNG Type C 
 754 GEAKLTNGEGKLTNGEAKLTNGEGKLTNGEAKLTNGEGKLTN-------GDSKLTNG Type D 
 754 GEAKLTNGEGKLTNG-----------------------------------DSKLTNG Type E 
 754 GEAKLTNGEGKLTNGEAKLTN-------GEAKLTNGEGKLTNGDAKLTNGDSKLTNG Type F 
 754 GEAKLTNGEGKLTNGE-------GKLTNGEAKLTNGEGKLTN-------GDSKLTNG Type G 
 754 GEAKLTNGEGKLTNGEGKLTNGEGKLTNGEAKLTNG--------------DSKLTNG Type H 
Figure 2 Tandem repeat variation in Plasmodium vivax DHPS.
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Due to emergence and widespread of drug resistant
strains of human Plasmodium species against che-
motherapeutic intervention agents, clinical trial for
monitoring drug efficacy over regular intervals as well as
monitoring mutation data in relevant genes related with
anti-malarial resistance are the crucial steps in deciding
scope of a drug in field. This study uncovers 1) progres-
sive increase in the frequency of quadruple mutant dhfr
genotypes, 2) limited point mutations in dhps among
Indian isolates, and 3) distinct pattern of anti-folate
resistance in Indian sub-continent linked with geogra-
phical regions.
Plasmodium vivax is still susceptible to chloroquine in
India [30,31] and anti-folate drugs are not used for treat-
ment of vivax malaria, therefore, the appearance of point
mutations in dhfr/dhps is surprising. This has been
explained earlier because of the use of sulphadoxine-pyri-
methamine to treat chloroquine-resistant P. falciparum is
creating selection pressure in the P. vivax population.
10 
1  2 
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6 
7 
8 
9 
12 
11 
1: Delhi, 2: Mohan Nagar, 3: Aligarh 
4: Mirzapur, 5: Panna, 6: Nadiad 
7: Navi Mumbai, 8: Goa, 9: Chennai 
10: Cuttack, 11: Kamrup, 12: Car Nicobar 
Wild type 
Single mutant 
Double mutant 
Triple mutant 
Quadruple mutant 
Type 1 
Type 2 
Type 3 
N=49 
N=68  N=38 
N=8 
N=19 
N=30 
N=44 
N=38 
N=16 
N=67 
N=76 
N=24 
Figure 3 Frequencies of Plasmodium vivax dhfr genotypes and their geographical clustering among Indian subcontinent.
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Page 5 of 7This has been reflected in the isolates of areas with
sympatricity of P. falciparum and P. vivax [23,25], which
presented a higher proportion of double and quadruple
mutant dhfr genotypes than other regions. Cotrimoxazole
(sulfamethoxazole and trimethoprim), an anti-microbial
drug that target bacterial dhfr/dhps,i sw i d e l yu s e di n
bacterial infection as prophylaxis, and has potential to
select mutant dhfr/dhps of malaria parasites [32,33].
Cotrimoxazole is being used in India to treat bacterial
infection in wide spectrum [34,35], which suggests that it
could be a potential factor to select anti-folate point
mutations in the Indian subcontinent. Other factors, i.e.
presumptive treatment of malaria without diagnosis and
use of S/P by private practitioners, cannot be ruled out.
The comprehensive analysis of point mutations in dhfr
among Indian sub-continent revealed three distinct clus-
ters/groups/types linked with geographical locations.
North and south India revealed a prevalence of wild and
double mutant dhfr, respectively, whereas north-eastern
and island regions revealed a high prevalence of quadru-
ple mutant dhfr genotype. Single to quintuple mutations
have been reported in dhfr b u to n l yt r i p l et oq u i n t u p l e
mutant alleles are known to confer high level of resis-
tance [36-38]. This strongly suggests that P. vivax iso-
lates from northern and southern part of India could be
sensitive to anti-folate drug, whereas isolates from
north-eastern state and Island regions will be resistant
to anti-folate drug.
A significant association between dhfr mutations and
tandem repeat polymorphism was observed in studied iso-
lates. The mutated dhfr genotype was exclusively asso-
ciated with Type-2 tandem repeat and is strongly
supported by previous study from India [23]. Further
quadruple mutant dhfr alleles were exclusively associated
with type 1 tandem repeat and are supported by earlier
studies from India [23], Thailand [38] and Myanmar [39],
however exception to this association was only showed by
as i n g l ei s o l a t ef r o mM y a n m a r [39]. These observations
speculate dhfr allele with type 1 tandem repeat could be
more prone for mutations and development of higher
level of resistance conferring genotypes. Therefore, it
could act as molecular marker to predict the risk of
mutant/higher level resistance conferring mutant geno-
types in any geographical area of Indian subcontinent.
Frequency of quadruple mutant dhfr genotype was
progressively increased in Kamrup isolates from 2005 to
2007 [23]. The high proportion of quadruple mutant
dhfr genotype in endemic area may be: 1) because of the
characteristics of mutant parasites associated with
higher gametocytogenesis [40-43] which favour trans-
mission of mutant parasites compared to wild type dhfr,
and 2) north-eastern states of India are highly endemic
for malaria and international borders with neighbouring
countries surround the region. The borders are very
porous and illegal migrations of people across the bor-
ders are very common thus, importing drug resistant
strains. The higher frequency of quadruple mutant dhfr
genotypes in the isolates of Myanmar (71%) and Thai-
land (96%) [39,44], supports for inflow of quadruple
mutant dhfr genotype in north-eastern states of India.
The development and spread of drug resistant parasite
strains is a major obstacle to the malaria elimination pro-
gramme. Therefore, it is essential to identify drug resis-
tance areas/regions on the basis of point mutations in
order to manage the national anti-malarial drug policy. In
this regard, this study revealed a higher and increasing
prevalence of quadruple mutant dhfr genotype in north-
eastern and Island regions, therefore, additional caution
may be taken for treatment of vivax malaria in these
regions to stop the flourishing of quadruple mutant dhfr
genotypes in remaining part of country. The study con-
cluded that P. vivax isolates from northern and southern
part of India could be susceptible to SP except for the iso-
lates from Car Nicobar (Island) and Assam (north-eastern
region). Geographical clustering of dhfr mutant genotypes
would provide a rationale for a more appropriate national
anti-malarial drug policy.
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